Cargando…
An integrated method for single cell proteomics with simultaneous measurements of intracellular drug concentration implicates new mechanisms for adaptation to KRAS(G12D) inhibitors
It is well established that a population of single human cells will often respond to the same drug treatment in a heterogeneous manner. In the context of chemotherapeutics, these diverse responses may lead to individual adaptation mechanisms and ultimately multiple distinct methods of resistance. Th...
Autor principal: | Orsburn, Benjamin C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680798/ https://www.ncbi.nlm.nih.gov/pubmed/38014353 http://dx.doi.org/10.1101/2023.11.18.567669 |
Ejemplares similares
-
Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRAS(G12D) inhibitor MRTX1133
por: Orsburn, Benjamin C.
Publicado: (2023) -
Metabolomic,
Proteomic, and Single-Cell Proteomic
Analysis of Cancer Cells Treated with the KRAS(G12D) Inhibitor
MRTX1133
por: Orsburn, Benjamin C.
Publicado: (2023) -
Comparative proteomics of a model MCF10A-KRas(G12V) cell line reveals a distinct molecular signature of the KRas(G12V) cell surface
por: Ye, Xiaoying, et al.
Publicado: (2016) -
Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021) -
TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)